{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:53:58Z","timestamp":1791348838993,"version":"4.3.1"},"reference-count":63,"publisher":"Rockefeller University Press","issue":"5","content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,5,9]]},"abstract":"<jats:p>Angiogenesis plays an essential role in several diseases of the eye and in the growth of solid tumors, but existing antiangiogenic therapies have limited benefits in several cases. We report the antiangiogenic effects of a monoclonal antibody, CL1-R2, in several animal models of neovascularization. CL1-R2 recognizes human CD160, a membrane receptor which is conserved in various mammal species. We show that CD160 is expressed on the endothelial cells of newly formed blood vessels in human colon carcinoma and mouse B16 melanoma but not in vessels of healthy tissues. CL1-R2 reduced fibroblast growth factor 2\u2013induced neovascularization in the rabbit cornea, in a mouse model of oxygen-induced retinopathy, and in a mouse Matrigel plug assay. Treatment of B16 melanoma-bearing mice with CL1-R2 combined with cyclophosphamide chemotherapy caused regression of the tumor vasculature and normalization of the remaining vessels as shown by Doppler ultrasonography, intravital microscopy, and histology. These studies validate CD160 as a potential new target in cases of human pathological ocular and tumor neoangiogenesis that do not respond or become resistant to existing antiangiogenic drugs.<\/jats:p>","DOI":"10.1084\/jem.20100810","type":"journal-article","created":{"date-parts":[[2011,4,12]],"date-time":"2011-04-12T09:58:02Z","timestamp":1302602282000},"page":"973-986","update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":43,"title":["A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor"],"prefix":"10.1084","volume":"208","author":[{"given":"Sophie","family":"Chabot","sequence":"first","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U1043, F-31300 Toulouse, France 1"},{"name":"Centre National de la Recherche Scientifique (CNRS) U5282, F-31300 Toulouse, France 2"},{"name":"Centre de Physiopathologie de Toulouse Purpan 3 , 4"},{"name":"Universit\u00e9 de Toulouse, Universit\u00e9 Paul Sabatier (UPS), F-31300 Toulouse, France 3 , 4"},{"name":"Centre de Physiopathologie de Toulouse Purpan 3 , 4"},{"name":"Universit\u00e9 de Toulouse, Universit\u00e9 Paul Sabatier (UPS), F-31300 Toulouse, France 3 , 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabila","family":"Jabrane-Ferrat","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U1043, F-31300 Toulouse, France 1"},{"name":"Centre National de la Recherche Scientifique (CNRS) U5282, F-31300 Toulouse, France 2"},{"name":"Centre de Physiopathologie de Toulouse Purpan 3 , 4"},{"name":"Universit\u00e9 de Toulouse, Universit\u00e9 Paul Sabatier (UPS), F-31300 Toulouse, France 3 , 4"},{"name":"Centre de Physiopathologie de Toulouse Purpan 3 , 4"},{"name":"Universit\u00e9 de Toulouse, Universit\u00e9 Paul Sabatier (UPS), F-31300 Toulouse, France 3 , 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Bigot","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de M\u00e9decine Paris-Descartes-Site Necker, Universit\u00e9 Paris-Descartes EA no. 2502, 75015 Paris, France 5"},{"name":"Service d\u2019Ophtalmologie, Centre Hospitalo-Universitaire Necker-Enfants-Malades, Assistance Publique-H\u00f4pitaux de Paris, 75015 Paris, France 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Tabiasco","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U1043, F-31300 Toulouse, France 1"},{"name":"Centre National de la Recherche Scientifique (CNRS) U5282, F-31300 Toulouse, France 2"},{"name":"Centre de Physiopathologie de Toulouse Purpan 3 , 4"},{"name":"Universit\u00e9 de Toulouse, Universit\u00e9 Paul Sabatier (UPS), F-31300 Toulouse, France 3 , 4"},{"name":"Centre de Physiopathologie de Toulouse Purpan 3 , 4"},{"name":"Universit\u00e9 de Toulouse, Universit\u00e9 Paul Sabatier (UPS), F-31300 Toulouse, France 3 , 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Provost","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de M\u00e9decine Paris-Descartes-Site Necker, Universit\u00e9 Paris-Descartes EA no. 2502, 75015 Paris, France 5"},{"name":"Service d\u2019Ophtalmologie, Centre Hospitalo-Universitaire Necker-Enfants-Malades, Assistance Publique-H\u00f4pitaux de Paris, 75015 Paris, France 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Golzio","sequence":"additional","affiliation":[{"name":"Centre de Physiopathologie de Toulouse Purpan 3 , 4"},{"name":"Universit\u00e9 de Toulouse, Universit\u00e9 Paul Sabatier (UPS), F-31300 Toulouse, France 3 , 4"},{"name":"Institut de Pharmacologie et de Biologie Structurale, CNRS, 31077 Toulouse, France 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Zaeem","family":"Noman","sequence":"additional","affiliation":[{"name":"Laboratoire d\u2019immunologie des tumeurs humaines, Institut Gustave Roussy, INSERM U753, 94805 Villejuif, France 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Giustiniani","sequence":"additional","affiliation":[{"name":"Equerre Bazin, H\u00f4pital Saint-Louis, INSERM U976, 75475 Paris Cedex 10, France 9"},{"name":"Universit\u00e9 Paris Diderot-Paris 7, 75000 Paris, France 10"},{"name":"Laboratoire de th\u00e9rapie cellulaire, Institut Jean Godinot, BP171 51056 Reims Cedex, France 11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Bellard","sequence":"additional","affiliation":[{"name":"Centre de Physiopathologie de Toulouse Purpan 3 , 4"},{"name":"Universit\u00e9 de Toulouse, Universit\u00e9 Paul Sabatier (UPS), F-31300 Toulouse, France 3 , 4"},{"name":"Institut de Pharmacologie et de Biologie Structurale, CNRS, 31077 Toulouse, France 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Brayer","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U1043, F-31300 Toulouse, France 1"},{"name":"Centre National de la Recherche Scientifique (CNRS) U5282, F-31300 Toulouse, France 2"},{"name":"Centre de Physiopathologie de Toulouse Purpan 3 , 4"},{"name":"Universit\u00e9 de Toulouse, Universit\u00e9 Paul Sabatier (UPS), F-31300 Toulouse, France 3 , 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Aguerre-Girr","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U1043, F-31300 Toulouse, France 1"},{"name":"Centre National de la Recherche Scientifique (CNRS) U5282, F-31300 Toulouse, France 2"},{"name":"Centre de Physiopathologie de Toulouse Purpan 3 , 4"},{"name":"Universit\u00e9 de Toulouse, Universit\u00e9 Paul Sabatier (UPS), F-31300 Toulouse, France 3 , 4"},{"name":"Centre de Physiopathologie de Toulouse Purpan 3 , 4"},{"name":"Universit\u00e9 de Toulouse, Universit\u00e9 Paul Sabatier (UPS), F-31300 Toulouse, France 3 , 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Meggetto","sequence":"additional","affiliation":[{"name":"Centre de Recherches en Canc\u00e9rologie de Toulouse, INSERM Unit\u00e9 Mixte de Recherche 1037\u2013Universit\u00e9 de Toulouse, UPS, F-31300 Toulouse, France 12"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Giuriato","sequence":"additional","affiliation":[{"name":"Centre de Recherches en Canc\u00e9rologie de Toulouse, INSERM Unit\u00e9 Mixte de Recherche 1037\u2013Universit\u00e9 de Toulouse, UPS, F-31300 Toulouse, France 12"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Malecaze","sequence":"additional","affiliation":[{"name":"Service d\u2019Ophtalmologie, Centre Hospitalo-Universitaire Toulouse, H\u00f4pital Purpan, Equipe Accueil Universitaire EA \u201cGR2DE\u201d de l\u2019Universit\u00e9 de Toulouse (UPS), F-31300 Toulouse, France 13"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Galiacy","sequence":"additional","affiliation":[{"name":"Service d\u2019Ophtalmologie, Centre Hospitalo-Universitaire Toulouse, H\u00f4pital Purpan, Equipe Accueil Universitaire EA \u201cGR2DE\u201d de l\u2019Universit\u00e9 de Toulouse (UPS), F-31300 Toulouse, France 13"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Ja\u00efs","sequence":"additional","affiliation":[{"name":"Service de Biostastistiques et Bioinformatique, Assistance Publique-H\u00f4pitaux de Paris, Centre Hospitalo-Universitaire Necker-Enfants-Malades, Universit\u00e9 Paris-Descartes EA no. 4067, 75015 Paris, France 14"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chose","sequence":"additional","affiliation":[{"name":"Matbiopharma, 91030 Evry Cedex, France 15"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Kadouche","sequence":"additional","affiliation":[{"name":"Matbiopharma, 91030 Evry Cedex, France 15"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem","family":"Chouaib","sequence":"additional","affiliation":[{"name":"Laboratoire d\u2019immunologie des tumeurs humaines, Institut Gustave Roussy, INSERM U753, 94805 Villejuif, France 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Teissi\u00e9","sequence":"additional","affiliation":[{"name":"Centre de Physiopathologie de Toulouse Purpan 3 , 4"},{"name":"Universit\u00e9 de Toulouse, Universit\u00e9 Paul Sabatier (UPS), F-31300 Toulouse, France 3 , 4"},{"name":"Institut de Pharmacologie et de Biologie Structurale, CNRS, 31077 Toulouse, France 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Abitbol","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de M\u00e9decine Paris-Descartes-Site Necker, Universit\u00e9 Paris-Descartes EA no. 2502, 75015 Paris, France 5"},{"name":"Service d\u2019Ophtalmologie, Centre Hospitalo-Universitaire Necker-Enfants-Malades, Assistance Publique-H\u00f4pitaux de Paris, 75015 Paris, France 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Bensussan","sequence":"additional","affiliation":[{"name":"Equerre Bazin, H\u00f4pital Saint-Louis, INSERM U976, 75475 Paris Cedex 10, France 9"},{"name":"Universit\u00e9 Paris Diderot-Paris 7, 75000 Paris, France 10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Le Bouteiller","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U1043, F-31300 Toulouse, France 1"},{"name":"Centre National de la Recherche Scientifique (CNRS) U5282, F-31300 Toulouse, France 2"},{"name":"Centre de Physiopathologie de Toulouse Purpan 3 , 4"},{"name":"Universit\u00e9 de Toulouse, Universit\u00e9 Paul Sabatier (UPS), F-31300 Toulouse, France 3 , 4"},{"name":"Centre de Physiopathologie de Toulouse Purpan 3 , 4"},{"name":"Universit\u00e9 de Toulouse, Universit\u00e9 Paul Sabatier (UPS), F-31300 Toulouse, France 3 , 4"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2011,4,11]]},"reference":[{"key":"2023072600414984100_bib1","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nature05249","article-title":"Corneal avascularity is due to soluble VEGF receptor-1","volume":"443","author":"Ambati","year":"2006","journal-title":"Nature."},{"key":"2023072600414984100_bib2","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.4049\/jimmunol.161.6.2780","article-title":"Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes","volume":"161","author":"Anumanthan","year":"1998","journal-title":"J. Immunol."},{"key":"2023072600414984100_bib3","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/sj.gt.3300841","article-title":"Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography","volume":"6","author":"Asselin-Paturel","year":"1999","journal-title":"Gene Ther."},{"key":"2023072600414984100_bib4","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.4049\/jimmunol.173.9.5349","article-title":"Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset","volume":"173","author":"Barakonyi","year":"2004","journal-title":"J. Immunol."},{"key":"2023072600414984100_bib5","first-page":"72","article-title":"BY55 (CD160)","volume":"1","author":"Bensussan","year":"2000","journal-title":"Protein Rev. Web."},{"key":"2023072600414984100_bib6","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat. Rev. Cancer."},{"key":"2023072600414984100_bib7","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1167\/iovs.06-0570","article-title":"Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis","volume":"48","author":"Bock","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2023072600414984100_bib8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nm1699","article-title":"Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy","volume":"14","author":"Buckanovich","year":"2008","journal-title":"Nat. Med."},{"key":"2023072600414984100_bib9","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.2741\/3504","article-title":"Tumor angiogenesis and molecular targets for therapy","volume":"14","author":"Cao","year":"2009","journal-title":"Front. Biosci."},{"key":"2023072600414984100_bib10","doi-asserted-by":"crossref","first-page":"ps3","DOI":"10.1126\/scitranslmed.3000399","article-title":"Optimizing the delivery of cancer drugs that block angiogenesis","volume":"2","author":"Cao","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"2023072600414984100_bib11","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/nature04478","article-title":"Angiogenesis in life, disease and medicine","volume":"438","author":"Carmeliet","year":"2005","journal-title":"Nature."},{"key":"2023072600414984100_bib12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat Rev Clin Oncol."},{"key":"2023072600414984100_bib13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000099253","article-title":"Immune privilege and angiogenic privilege of the cornea","volume":"92","author":"Cursiefen","year":"2007","journal-title":"Chem. Immunol. Allergy."},{"key":"2023072600414984100_bib14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch. Ophthalmol."},{"key":"2023072600414984100_bib15","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1073\/pnas.0607542104","article-title":"Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis","volume":"104","author":"Dorrell","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023072600414984100_bib16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/IJG.0b013e318170a747","article-title":"Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients","volume":"18","author":"Duch","year":"2009","journal-title":"J. Glaucoma."},{"key":"2023072600414984100_bib17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/pmic.200400902","article-title":"Peptide mass fingerprinting by matrix-assisted laser desorption ionization mass spectrometry of proteins detected by immunostaining on nitrocellulose","volume":"5","author":"Dufresne-Martin","year":"2005","journal-title":"Proteomics."},{"key":"2023072600414984100_bib18","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1182\/blood-2005-03-0889","article-title":"Inhibition of pathologic retinal neovascularization by alpha-defensins","volume":"106","author":"Economopoulou","year":"2005","journal-title":"Blood."},{"key":"2023072600414984100_bib19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ultrasmedbio.2006.09.011","article-title":"Methodology for quantifying interactions between perfusion evaluated by DCE-US and hypoxia throughout tumor growth","volume":"33","author":"Elie","year":"2007","journal-title":"Ultrasound Med. Biol."},{"key":"2023072600414984100_bib20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat. Rev. Cancer."},{"key":"2023072600414984100_bib21","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/sj.eye.6703008","article-title":"Looking beyond Lucentis on the management of macular degeneration","volume":"22","author":"Fletcher","year":"2008","journal-title":"Eye (Lond.)."},{"key":"2023072600414984100_bib22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrd2115","article-title":"Angiogenesis: an organizing principle for drug discovery?","volume":"6","author":"Folkman","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"2023072600414984100_bib23","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1182\/blood-2005-12-019919","article-title":"Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells","volume":"108","author":"Fons","year":"2006","journal-title":"Blood."},{"key":"2023072600414984100_bib24","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/0008-5472.671.65.3","article-title":"Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies","volume":"65","author":"Gerber","year":"2005","journal-title":"Cancer Res."},{"key":"2023072600414984100_bib25","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.4161\/cbt.6.8.4508","article-title":"Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy","volume":"6","author":"Giuriato","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"2023072600414984100_bib26","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/nature07424","article-title":"A role for VEGF as a negative regulator of pericyte function and vessel maturation","volume":"456","author":"Greenberg","year":"2008","journal-title":"Nature."},{"key":"2023072600414984100_bib27","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/j.1755-3768.2009.01571.x","article-title":"The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization","volume":"88","author":"Habot-Wilner","year":"2010","journal-title":"Acta Ophthalmol. (Copenh.)."},{"key":"2023072600414984100_bib28","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-03-3126","article-title":"Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression","volume":"64","author":"Hamano","year":"2004","journal-title":"Cancer Res."},{"key":"2023072600414984100_bib29","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/nature06868","article-title":"Vascular normalization in Rgs5-deficient tumours promotes immune destruction","volume":"453","author":"Hamzah","year":"2008","journal-title":"Nature."},{"key":"2023072600414984100_bib30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1159\/000224783","article-title":"Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats","volume":"42","author":"Hashemian","year":"2009","journal-title":"Ophthalmic Res."},{"key":"2023072600414984100_bib31","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1084\/jem.20091846","article-title":"Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma","volume":"207","author":"Helfrich","year":"2010","journal-title":"J. Exp. Med."},{"key":"2023072600414984100_bib32","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1054\/mehy.1999.0848","article-title":"Is fractal geometry useful in medicine and biomedical sciences?","volume":"54","author":"Heymans","year":"2000","journal-title":"Med. Hypotheses."},{"key":"2023072600414984100_bib33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/ICO.0b013e318160d019","article-title":"Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs","volume":"27","author":"Hurmeric","year":"2008","journal-title":"Cornea."},{"key":"2023072600414984100_bib34","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.ophtha.2008.10.011","article-title":"Bevacizumab for corneal neovascularization","volume":"116","author":"Jacobs","year":"2009","journal-title":"Ophthalmology."},{"key":"2023072600414984100_bib35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science."},{"key":"2023072600414984100_bib36","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/nrc778","article-title":"Dissecting tumour pathophysiology using intravital microscopy","volume":"2","author":"Jain","year":"2002","journal-title":"Nat. Rev. Cancer."},{"key":"2023072600414984100_bib37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10585-008-9234-7","article-title":"Intravital microscopy of tumor angiogenesis and regression in the dorsal skin fold chamber: mechanistic insights and preclinical testing of therapeutic strategies","volume":"26","author":"Koehl","year":"2009","journal-title":"Clin. Exp. Metastasis."},{"key":"2023072600414984100_bib38","doi-asserted-by":"publisher","first-page":"16963","DOI":"10.1073\/pnas.012681099","article-title":"Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity","volume":"99","author":"Le Bouteiller","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023072600414984100_bib39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","article-title":"Longitudinal data analysis using generalized linear models","volume":"73","author":"Liang","year":"1986","journal-title":"Biometrika."},{"key":"2023072600414984100_bib40","first-page":"529","article-title":"Antiangiogenic therapy: creating a unique \u201cwindow\u201d of opportunity","volume":"6","author":"Lin","year":"2004","journal-title":"Cancer Cell."},{"key":"2023072600414984100_bib41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3322\/caac.20003","article-title":"Novel agents on the horizon for cancer therapy","volume":"59","author":"Ma","year":"2009","journal-title":"CA Cancer J. Clin."},{"key":"2023072600414984100_bib42","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.4049\/jimmunol.175.7.4426","article-title":"Murine CD160, Ig-like receptor on NK cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation","volume":"175","author":"Maeda","year":"2005","journal-title":"J. Immunol."},{"key":"2023072600414984100_bib43","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0076-6879(07)26016-1","article-title":"Intravital imaging and cell invasion","volume":"426","author":"Makale","year":"2007","journal-title":"Methods Enzymol."},{"key":"2023072600414984100_bib44","first-page":"2731","article-title":"Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water","volume":"62","author":"Man","year":"2002","journal-title":"Cancer Res."},{"key":"2023072600414984100_bib45","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)","volume":"91","author":"Manzano","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"2023072600414984100_bib46","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/bjo.2008.151472","article-title":"Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab","volume":"93","author":"Moraczewski","year":"2009","journal-title":"Br. J. Ophthalmol."},{"key":"2023072600414984100_bib47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/02713680802607740","article-title":"The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas","volume":"34","author":"Oh","year":"2009","journal-title":"Curr. Eye Res."},{"key":"2023072600414984100_bib48","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/427695a","article-title":"Pathology: cancer cells compress intratumour vessels","volume":"427","author":"Padera","year":"2004","journal-title":"Nature."},{"key":"2023072600414984100_bib49","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"P\u00e0ez-Ribes","year":"2009","journal-title":"Cancer Cell."},{"key":"2023072600414984100_bib50","first-page":"519","article-title":"A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor","volume":"67","author":"Passaniti","year":"1992","journal-title":"Lab. Invest."},{"key":"2023072600414984100_bib51","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/nbt1004-1198","article-title":"Genentech discloses safety concerns over Avastin","volume":"22","author":"Ratner","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"2023072600414984100_bib52","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrd2241","article-title":"Development trends for monoclonal antibody cancer therapeutics","volume":"6","author":"Reichert","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"2023072600414984100_bib53","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2023072600414984100_bib54","first-page":"657","article-title":"Technology evaluation: bevacizumab, Genentech\/Roche","volume":"5","author":"Salgaller","year":"2003","journal-title":"Curr. Opin. Mol. Ther."},{"key":"2023072600414984100_bib55","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10456-007-9068-y","article-title":"Ocular drug development\u2014future directions","volume":"10","author":"Sherris","year":"2007","journal-title":"Angiogenesis."},{"key":"2023072600414984100_bib56","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/labinvest.3700526","article-title":"Antiangiogenesis to treat cancer and intraocular neovascular disorders","volume":"87","author":"Shojaei","year":"2007","journal-title":"Lab. Invest."},{"key":"2023072600414984100_bib57","first-page":"101","article-title":"Oxygen-induced retinopathy in the mouse","volume":"35","author":"Smith","year":"1994","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2023072600414984100_bib58","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nature08151","article-title":"CCR3 is a target for age-related macular degeneration diagnosis and therapy","volume":"460","author":"Takeda","year":"2009","journal-title":"Nature."},{"key":"2023072600414984100_bib59","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/jcp.21445","article-title":"Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels","volume":"217","author":"Ueno","year":"2008","journal-title":"J. Cell. Physiol."},{"key":"2023072600414984100_bib60","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ijc.2910470211","article-title":"Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line","volume":"47","author":"Welch","year":"1991","journal-title":"Int. J. Cancer."},{"key":"2023072600414984100_bib61","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/00949659308811554","article-title":"Generalized linear mixed models a pseudo-likelihood approach","volume":"48","author":"Wolfinger","year":"1993","journal-title":"Journal of Statistical Computation and Simulation."},{"key":"2023072600414984100_bib62","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1167\/iovs.07-1175","article-title":"Interaction between bevacizumab and murine VEGF-A: a reassessment","volume":"49","author":"Yu","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2023072600414984100_bib63","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s00417-009-1066-x","article-title":"Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygen-induced retinopathy","volume":"247","author":"Zhang","year":"2009","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/208\/5\/973\/1742583\/jem_20100810.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/208\/5\/973\/1742583\/jem_20100810.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:42:59Z","timestamp":1690332179000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/208\/5\/973\/41213\/A-novel-antiangiogenic-and-vascular-normalization"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,11]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5,9]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20100810","relation":{},"ISSN":["1540-9538","0022-1007"],"issn-type":[{"value":"1540-9538","type":"electronic"},{"value":"0022-1007","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4,11]]}}}